Site search

Clear filter
2831 results for '' found
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.
/
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who
/
IDENTIFYING IMMUNE AND INFECTIOUS BIOMARKERS OF EARLY AND LATE ALLOGRAFT DYSFUNCTION FOLLOWING LUNG TRANSPLANTATION (Trial Not Registered)
IDENTIFYING IMMUNE AND INFECTIOUS BIOMARKERS OF EARLY AND LATE ALLOGRAFT DYSFUNCTION FOLLOWING LUNG TRANSPLANTATION (Trial Not Registered)
/
LuMIERE: A Phase 1/2 Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participa
LuMIERE: A Phase 1/2 Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participa
/
A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations (LOXO-IDH-20001) (NCT04603001)
A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations (LOXO-IDH-20001) (NCT04603001)
/
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/
/
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemi
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemi
/
Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement (NCT02701283)
Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement (NCT02701283)
/
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Subjects and in Subjects with Parkinson’s disease (N
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Subjects and in Subjects with Parkinson’s disease (N
/
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous tre
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous tre
/
26 27 28 29 30